412 related articles for article (PubMed ID: 30585770)
1. Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes.
Forlenza GP; Pinhas-Hamiel O; Liljenquist DR; Shulman DI; Bailey TS; Bode BW; Wood MA; Buckingham BA; Kaiserman KB; Shin J; Huang S; Lee SW; Kaufman FR
Diabetes Technol Ther; 2019 Jan; 21(1):11-19. PubMed ID: 30585770
[TBL] [Abstract][Full Text] [Related]
2. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes.
Garg SK; Weinzimer SA; Tamborlane WV; Buckingham BA; Bode BW; Bailey TS; Brazg RL; Ilany J; Slover RH; Anderson SM; Bergenstal RM; Grosman B; Roy A; Cordero TL; Shin J; Lee SW; Kaufman FR
Diabetes Technol Ther; 2017 Mar; 19(3):155-163. PubMed ID: 28134564
[TBL] [Abstract][Full Text] [Related]
3. In-Clinic Evaluation of the MiniMed 670G System "Suspend Before Low" Feature in Children with Type 1 Diabetes.
Wood MA; Shulman DI; Forlenza GP; Bode BW; Pinhas-Hamiel O; Buckingham BA; Kaiserman KB; Liljenquist DR; Bailey TS; Shin J; Huang S; Chen X; Cordero TL; Lee SW; Kaufman FR
Diabetes Technol Ther; 2018 Nov; 20(11):731-737. PubMed ID: 30299976
[TBL] [Abstract][Full Text] [Related]
4. Glycemic outcomes of children 2-6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial.
Forlenza GP; Ekhlaspour L; DiMeglio LA; Fox LA; Rodriguez H; Shulman DI; Kaiserman KB; Liljenquist DR; Shin J; Lee SW; Buckingham BA
Pediatr Diabetes; 2022 May; 23(3):324-329. PubMed ID: 35001477
[TBL] [Abstract][Full Text] [Related]
5. Retrospective Analysis of 3-Month Real-World Glucose Data After the MiniMed 670G System Commercial Launch.
Stone MP; Agrawal P; Chen X; Liu M; Shin J; Cordero TL; Kaufman FR
Diabetes Technol Ther; 2018 Oct; 20(10):689-692. PubMed ID: 30160523
[TBL] [Abstract][Full Text] [Related]
6. Safety and Glycemic Outcomes During the MiniMed
Pihoker C; Shulman DI; Forlenza GP; Kaiserman KB; Sherr JL; Thrasher JR; Buckingham BA; Kipnes MS; Bode BW; Carlson AL; Lee SW; Latif K; Liljenquist DR; Slover RH; Dai Z; Niu F; Shin J; Jonkers RAM; Roy A; Grosman B; Vella M; Cordero TL; McVean J; Rhinehart AS; Vigersky RA;
Diabetes Technol Ther; 2023 Nov; 25(11):755-764. PubMed ID: 37782145
[No Abstract] [Full Text] [Related]
7. Safety, metabolic and psychological outcomes of Medtronic MiniMed 670G in children, adolescents and young adults: a systematic review.
Mameli C; Smylie GM; Galati A; Rapone B; Cardona-Hernandez R; Zuccotti G; Delvecchio M
Eur J Pediatr; 2023 May; 182(5):1949-1963. PubMed ID: 36809498
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Prior Continuous Glucose Monitoring Use on Glycemic Outcomes in the Pivotal Trial of the MiniMed
Cordero TL; Garg SK; Brazg R; Bailey TS; Shin J; Lee SW; Kaufman FR
Diabetes Technol Ther; 2017 Dec; 19(12):749-752. PubMed ID: 29148821
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Real-Life Usage of MiniMed 670G Automode in Children with Type 1 Diabetes Less than 7 Years Old.
Salehi P; Roberts AJ; Kim GJ
Diabetes Technol Ther; 2019 Aug; 21(8):448-451. PubMed ID: 31166801
[TBL] [Abstract][Full Text] [Related]
10. 10-Day structured initiation protocol from multiple daily injection to hybrid closed-loop system in children and adolescents with type 1 diabetes.
Petrovski G; Al Khalaf F; Campbell J; Fisher H; Umer F; Hussain K
Acta Diabetol; 2020 Jun; 57(6):681-687. PubMed ID: 31953687
[TBL] [Abstract][Full Text] [Related]
11. Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System.
Messer LH; Forlenza GP; Sherr JL; Wadwa RP; Buckingham BA; Weinzimer SA; Maahs DM; Slover RH
Diabetes Care; 2018 Apr; 41(4):789-796. PubMed ID: 29444895
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
Jendle J; Pöhlmann J; de Portu S; Smith-Palmer J; Roze S
Diabetes Technol Ther; 2019 Mar; 21(3):110-118. PubMed ID: 30785311
[TBL] [Abstract][Full Text] [Related]
13. Switching from Suspend-Before-Low Insulin Pump Technology to a Hybrid Closed-Loop System Improves Glucose Control and Reduces Glucose Variability: A Retrospective Observational Case-Control Study.
Lepore G; Scaranna C; Corsi A; Dodesini AR; Trevisan R
Diabetes Technol Ther; 2020 Apr; 22(4):321-325. PubMed ID: 31617752
[TBL] [Abstract][Full Text] [Related]
14. Feasibility Study of a Hybrid Closed-Loop System with Automated Insulin Correction Boluses.
Nimri R; Grosman B; Roy A; Nir J; Fisch Shvalb N; Kurtz N; Loewenthal N; Gillon-Keren M; Muller I; Atlas E; Phillip M
Diabetes Technol Ther; 2021 Apr; 23(4):268-276. PubMed ID: 33185480
[No Abstract] [Full Text] [Related]
15. Glucose Control in Adults with Type 1 Diabetes Using a Medtronic Prototype Enhanced-Hybrid Closed-Loop System: A Feasibility Study.
Lee MH; Vogrin S; Paldus B; Jones HM; Obeyesekere V; Sims C; Wyatt SA; Ward GM; McAuley SA; MacIsaac RJ; Krishnamurthy B; Sundararajan V; Jenkins AJ; O'Neal DN
Diabetes Technol Ther; 2019 Sep; 21(9):499-506. PubMed ID: 31264889
[No Abstract] [Full Text] [Related]
16. One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes.
Petrovski G; Al Khalaf F; Campbell J; Umer F; Almajaly D; Hamdan M; Hussain K
Acta Diabetol; 2021 Feb; 58(2):207-213. PubMed ID: 33044604
[TBL] [Abstract][Full Text] [Related]
17. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial.
Bergenstal RM; Nimri R; Beck RW; Criego A; Laffel L; Schatz D; Battelino T; Danne T; Weinzimer SA; Sibayan J; Johnson ML; Bailey RJ; Calhoun P; Carlson A; Isganaitis E; Bello R; Albanese-O'Neill A; Dovc K; Biester T; Weyman K; Hood K; Phillip M;
Lancet; 2021 Jan; 397(10270):208-219. PubMed ID: 33453783
[TBL] [Abstract][Full Text] [Related]
18. Fast-Acting Insulin Aspart Use with the MiniMed
Hsu L; Buckingham B; Basina M; Ekhlaspour L; von Eyben R; Wang J; Lal RA
Diabetes Technol Ther; 2021 Jan; 23(1):1-7. PubMed ID: 32520594
[No Abstract] [Full Text] [Related]
19. One Year Clinical Experience of the First Commercial Hybrid Closed-Loop System.
Lal RA; Basina M; Maahs DM; Hood K; Buckingham B; Wilson DM
Diabetes Care; 2019 Dec; 42(12):2190-2196. PubMed ID: 31548247
[TBL] [Abstract][Full Text] [Related]
20. Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMed
Grosman B; Wu D; Parikh N; Roy A; Voskanyan G; Kurtz N; Sturis J; Cohen O; Ekelund M; Vigersky R
Comput Methods Programs Biomed; 2021 Jun; 205():106087. PubMed ID: 33873075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
